CALIPER LIFE SCIENCES INC
Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.
Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.
“The commercial success of our LabChip products depends upon market acceptance of the merits of our drug discovery and automated electrophoresis separations systems by pharmaceutical and biotechnology companies, academic research centers and other companies that rely upon laboratory experimentation.”
“Failure to maintain our credit facility borrowing base, raise additional capital or generate the significant capital necessary to expand our operations and invest in new products could reduce our ability to compete and result in lower revenue.”
“Turmoil in the world's financial markets, such as the financial crisis in 2008 from which global markets are still recovering, may make it difficult or impossible for us to raise additional capital.”
“Failure to remain in compliance with the covenants included in our revolving credit facility could interfere with or prevent our ability to obtain additional advances under this credit facility.”
“The delay, termination or non-renewal of a large multi-year contract or the loss of, or a significant reduction in, sales to any of our significant customers could harm our operating results.”
“We currently derive, and we expect to continue to derive, a significant percentage of our total revenue from a relatively small number of customers.”
“If the EPA experiences a reduction in its federal funding, elects not to proceed with the program or elects to reduce the number of compounds to be screened by us pursuant to this contract, our revenue may decline or grow more slowly than we currently expect.”
“We receive significant revenue from out-licensing our patent estates for in vivo optical imaging methods and microfluidic technology, and may not be able to replace such revenue upon the expiration of those patents.”